πŸ‡ΊπŸ‡Έ FDA
Patent

US 11141479

Stable anti-OSMR antibody formulation

granted A61KA61K2039/505A61K2039/545

Quick answer

US patent 11141479 (Stable anti-OSMR antibody formulation) held by Kiniksa Pharmaceuticals, GmbH expires Mon Oct 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Kiniksa Pharmaceuticals, GmbH
Grant date
Tue Oct 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K2039/505, A61K2039/545, A61K39/3955, A61P